TFF, Augmenta Bioworks partner on COVID-19 mAbs

By The Science Advisory Board staff writers

November 2, 2020 -- TFF Pharmaceuticals and Augmenta Bioworks have agreed to work together to develop COVID-19 monoclonal antibody (mAb) therapies.

The companies will apply TFF Pharmaceuticals' thin-film freezing (TFF) technology to Augmenta's human-derived mAbs as a potential treatment for COVID-19. The technology will be used to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients, according to their agreement.

The companies also agreed to develop formulations suitable for parenteral administration. The TFF dry powder formulas would be reconstituted, potentially mitigating the impacts of cold-chain storage and handling.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.